Form 8-K - Current report:
SEC Accession No. 0000950170-25-091210
Filing Date
2025-06-30
Accepted
2025-06-30 08:00:28
Documents
11
Period of Report
2025-06-27
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ubx-20250627.htm   iXBRL 8-K 74906
2 EX-2.1 ubx-ex2_1.htm EX-2.1 29565
  Complete submission text file 0000950170-25-091210.txt   220335

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ubx-20250627.xsd EX-101.SCH 25005
13 EXTRACTED XBRL INSTANCE DOCUMENT ubx-20250627_htm.xml XML 4538
Mailing Address 285 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 285 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 416-1192
Unity Biotechnology, Inc. (Filer) CIK: 0001463361 (see all company filings)

EIN.: 264726035 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38470 | Film No.: 251088790
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)